Evaluation Of Spinelink® Fixation In The Treatment Of Degenerative Spondylolisthesis And Spinal Instability

Degenerative Disc Disease Clinical Trial

Official title:

A Multicenter Prospective Patient Outcome Evaluation Of Spinelink® Fixation In The Treatment Of Degenerative Spondylolisthesis And Spinal Instability

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00726310
• Other study ID #: CS-044
• Status: Completed
• Start date: May 2000
• Est. completion date: November 2009

Study information

• Verified date: February 2020
• Source: Zimmer Biomet
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this open, multi-center study is to prospectively collect outcome data on patients who are having lumbar spinal fusion surgery with implantation of the SpineLink® system.

Description:

This will be an open, prospective, multi-center outcome study. This study will be conducted at up to ten centers, each of which will enroll approximately 20 patients. A maximum of 200 patients will be enrolled. This patient sample size will allow statistical comparison to historical literature and allow an inter-center comparison of outcome. Enrollment into the study may include all patients who have lumbar spinal fusion performed. All spinal fusion surgery will be performed using the EBI SpineLink® system.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 202
• Est. completion date: November 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. The patient has demonstrated Grade I or Grade II degenerative spondylolisthesis exhibited by maximum slippage on flexion and extension radiographs with symptoms that include back pain and/or leg pain with spinal fusion indicated, or spinal instability as evidenced by greater than 3 mm of translational motion or greater than 10 degrees of angular motion between the involved vertebrae as evidenced by flexion-extension radiographs.

2. This surgery will be the primary fusion attempt with no more than three (3) vertebrae or 2 disc spaces involved.

3. The patient must be available for yearly follow-up in the study until completion of the 24 month evaluation.

4. The patient must be skeletally mature (epiphyses closed).

5. Bone grafting material must be limited to autograft and/or bone-bank allograft.

6. The patient must be willing to comply with the treatment regimen, follow-up requirements, and have the legal ability to give informed consent.

Exclusion Criteria:

1. Patients with supplemental spinal internal fixation devices previously implanted at any other level and/or a previous fusion attempt at the involved level(s) (no interbody fusions, salvage procedures, or prior hardware).

2. Patients with other pathology at the involved spinal level, e.g., osteomyelitis, Paget's disease, pathologic fracture, etc.

3. Patients with a disease entity or condition that totally precludes the possibility of bony fusion such as known active cancer, etc.

4. Patients who have significant metabolic diseases including insulin dependent diabetes, renal dysfunction, etc.

5. Patients involved in personal injury litigation.

6. Pregnant or nursing females.

7. Patient in whom unapproved biologicals (e.g. BMP-2) or bone substitute materials (e.g. Grafton) would be used at the fusion site.

8. Patients who are unable to understand and sign an informed consent or who, in the opinion of the investigator, would be psychologically unwilling or unable to understand or complete the protocol, especially those unwilling or unable to participate in the follow-up.

Related Conditions & MeSH terms

• Degenerative Disc Disease
• Degenerative Spondylolisthesis
• Intervertebral Disc Degeneration
• Spondylolisthesis

Intervention

Device:
• SpineLink® , SpineLink® II
Spine plate system for lumbar spinal fusions

Locations

Country	Name	City	State
United States	Rogozinski Orthopedic Clinic	Jacksonville	Florida
United States	Alvarado Orthopedic Clinic	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Zimmer Biomet

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of successful fusions achieved	AP radiographs will be evaluated for the evidence of bridging virgin trabecular bone across the fusion mass. In order for a patient to be considered fused, A/P radiographs must show evidence of bridging virgin trabecular bone across the fusion mass.	24 Months
Secondary	Neurologic Assessment	Maintenance or Improvement	24 Months
Secondary	Radiographic Fusion Grade	Radiographic fusion grade will be assessed at each follow up, as defined by Dawson et al. 8, as follows: A0 = Pseudarthrosis A1 = Unilateral Pseudarthrosis A2 = Insufficient Unilateral Bone Mass A3 = Contiguous Fusion without Hypertrophy A4 = Solid Fusion with Hypertrophy of Fusion Mass	24 Months
Secondary	SF-36 Health Survey	Health Survey	24 Months